Shamim Ruff's most recent trade in Reata Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 8,235 Class A common stock done at an average price of $164.5 . Disclosure was reported to the exchange on July 28, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Sale of securities on an exchange or to another person at price $ 164.53 per share. | 28 Jul 2023 | 8,235 | 7,359 (0%) | 0% | 164.5 | 1,354,887 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 92.20 per share. | 28 Jul 2023 | 6,666 | 15,275 (0%) | 0% | 92.2 | 614,605 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 6,666 | 3,334 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 1,250 | 0 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 92.20 per share. | 28 Jul 2023 | 1,250 | 8,609 (0%) | 0% | 92.2 | 115,250 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 319 | 0 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 92.20 per share. | 28 Jul 2023 | 319 | 15,594 (0%) | 0% | 92.2 | 29,412 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 2,137 | 2,137 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 1,682 | 7,359 (0%) | 0% | 93.6 | 157,452 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 576 | 576 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 454 | 5,677 (0%) | 0% | 93.6 | 42,499 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Sale of securities on an exchange or to another person at price $ 83.73 per share. | 10 Mar 2023 | 5,740 | 5,223 (0%) | 0% | 83.7 | 480,610 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.76 per share. | 10 Mar 2023 | 4,215 | 10,963 (0%) | 0% | 34.8 | 146,513 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 4,215 | 1,405 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.76 per share. | 10 Mar 2023 | 1,326 | 6,748 (0%) | 0% | 34.8 | 46,092 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 1,326 | 443 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 199 | 0 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.32 per share. | 10 Mar 2023 | 199 | 5,422 (0%) | 0% | 27.3 | 5,437 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 5,620 | 5,620 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 3,883 | 5,223 (0%) | 0% | 34.8 | 134,973 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 1,769 | 1,769 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 1,222 | 1,340 (0%) | 0% | 34.8 | 42,477 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 199 | 199 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 03 Jan 2022 | 118 | 118 (0%) | 0% | 27.3 | 3,224 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 780 | 780 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 1,250 | 1,250 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Shamim Ruff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 319 | 319 | - | - | Stock Option (right to buy) |